Erythropoietin reduces lipopolysaccharide-induced cell damage and midkine secretion in U937 human histiocytic lymphoma cells
ADVANCES IN THERAPY, cilt.25, sa.5, ss.502-514, 2008 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 25 Sayı: 5
- Basım Tarihi: 2008
- Doi Numarası: 10.1007/s12325-008-0055-5
- Dergi Adı: ADVANCES IN THERAPY
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Sayfa Sayıları: ss.502-514
- Anahtar Kelimeler: erythropoietin, lipopolysaccharide, midkine, tumour necrosis factor alpha, interleukin-6, HEPARIN-BINDING CYTOKINE, CEREBRAL MALARIA, GROWTH-FACTOR, RECEPTOR, MICE, APOPTOSIS, SURVIVAL, DEATH
- Ankara Üniversitesi Adresli: Evet
Özet
Introduction: Erythropoietin (EPO) is a haematopoietic stimulatory protein that is used to treat anaemia in patients on dialysis. In addition, EPO has been shown to have anti-inflammatory properties, which may be important as dialysis patients tend to exist within a chronic, low-grade inflammatory state, and tend to be more susceptible to infections. It has been suggested that EPO has direct immunomodulatory potency on monocytes/macrophages.